TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30295328

Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation (LAI) with a 2940 nm Er:YAG-laser (20 Hz, 50 μs, 20 mJ, PIPS tip at the canal entrance)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Eddy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated irrigation (UAI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EndoActivator (EA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Needle irrigation (NI)
Number of subjects: 80
Study: 30650500

Group type: EXPERIMENTAL
Intervention: Modified Chaihu Guizhi Decoction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alendronate sodium 70 mg each week
Number of subjects: 40
Study: 26687960

Group type: EXPERIMENTAL
Intervention: Writing questions for practice examinations
Number of subjects: 206

Group type: COMPARATOR
Intervention: Practice test scores, USMLE Step 1 scores, previous ABSITE scores
Number of subjects: 206
Study: 25085304

Group type: EXPERIMENTAL
Intervention: Fluoride delivery system (Opal Seal; Ultradent Products)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard treatment (Transbond XT; 3M Unitek)
Number of subjects: 22
Study: 22309114

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Nevirapine (NVP)
Number of subjects: 650
Study: 19557208

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily added to ICS or ICS/LABA therapy
Number of subjects: 301
Study: 18372683

Group type: EXPERIMENTAL
Intervention: Intermittent artificial gravity (AG) via short radius centrifugation (SRC) for 60 min daily during bed rest
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no SRC loading)
Number of subjects: 8
Study: 15812098

Group type: EXPERIMENTAL
Intervention: Internist involvement in care (intervention group)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual care (usual-care group)
Number of subjects: 139
Study: 12059822

Group type: EXPERIMENTAL
Intervention: Midazolam 0.02 mg.kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 0.25 mg.kg(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline 2 ml (placebo)
Number of subjects: 60
Study: 10221441

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 48
Study: 8583658

Group type: EXPERIMENTAL
Intervention: Amrinone 0.5 mg.kg‐1 administered in the venous reservoir near the end of cardiopulmonary bypass (CPB) and doses of 1 and 5 micrograms.kg‐1.min‐1 by intravenous infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Amrinone (group C)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group A (no amrinone)
Number of subjects: 17
Study: 2749352

Group type: EXPERIMENTAL
Intervention: Vitamin B6 treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Repeat electrodiagnostic testing
Number of subjects: 15
Study: 6268475

Group type: EXPERIMENTAL
Intervention: Guar gum (21 g/day in three divided doses at main meals)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30476543

Group type: EXPERIMENTAL
Intervention: Biomarker CRT Score of 0
Number of subjects: 758

Group type: COMPARATOR
Intervention: Composite of clinical variables
Number of subjects: 758
Study: 27560946

Group type: EXPERIMENTAL
Intervention: HCP0911 (fixed-dose combination of clopidogrel and aspirin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Separate treatment with daily 75 mg clopidogrel plus 100 mg aspirin
Number of subjects: 30
Study: 26152318

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 31
Study: 22617861

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) at a target dose of 1.2 mg/kg per day
Number of subjects: 125

Group type: COMPARATOR
Intervention: Atomoxetine (ATX)
Number of subjects: 125
Study: 23327971

Group type: EXPERIMENTAL
Intervention: High-fat diet (HF: 1,974 kcal, 34% carbohydrate, 56% fat)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control diet (CON: 1,224 kcal, 55% carbohydrate, 30% fat)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control diet (CON)
Number of subjects: 6
Study: 20053533

Group type: EXPERIMENTAL
Intervention: Dietary glycemic load (GL)
Number of subjects: 878
Study: 19463294

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 51
Study: 15825240

Group type: EXPERIMENTAL
Intervention: Computerized motor-skill analyzer for the lower limb
Number of subjects: 0
Study: 12440843

Group type: EXPERIMENTAL
Intervention: Anthroposophical herbal remedy (20 drops 4 times daily for 4 weeks)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 10368042

Group type: EXPERIMENTAL
Intervention: 3 x 150 U/kg per week i.v.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3 x 300 U/kg per week i.v.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3 x 150 U/kg per week s.c.
Number of subjects: 50
Study: 7575310

Group type: EXPERIMENTAL
Intervention: P6 acupressure
Number of subjects: 64

Group type: COMPARATOR
Intervention: dummy-point acupressure
Number of subjects: 64

Group type: COMPARATOR
Intervention: sham acupressure
Number of subjects: 64
Study: 2373128

Group type: EXPERIMENTAL
Intervention: Org 3770 (30 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7100036

Group type: EXPERIMENTAL
Intervention: NSAID (4 different types prescribed for one week each over 4 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Retrospective NSAID prescribing in 164 patients
Number of subjects: 36
Study: 31549178

Group type: EXPERIMENTAL
Intervention: Switching to prasugrel (Switched Group; n=12)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Continuing to receive clopidogrel (Continued Group; n=11)
Number of subjects: 96
Study: 31162941

Group type: EXPERIMENTAL
Intervention: Chronic ankle instability (CAI) group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (individuals without CAI)
Number of subjects: 100
Study: 28993052

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg intravenously every 2 weeks)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study: 26472097

Group type: EXPERIMENTAL
Intervention: Fractional microneedling radiofrequency (FMR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bipolar radiofrequency (BR)
Number of subjects: 20
Study: 23864788

Group type: EXPERIMENTAL
Intervention: Propranolol (PR)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propranolol plus Isosorbide-5-mononitrate (PR plus ISMN)
Number of subjects: 48
Study: 22551440

Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin-based chemotherapy with or without docetaxel
Number of subjects: 520
Study: 19145228

Group type: EXPERIMENTAL
Intervention: rTMS targeted with neuro-navigation (n=24)
Number of subjects: 51

Group type: COMPARATOR
Intervention: rTMS applied using standard localization technique (n=27)
Number of subjects: 51
Study: 17191248

Group type: EXPERIMENTAL
Intervention: 3D radial pulse sequence with TE of 0.2 ms
Number of subjects: 23
Study: 15135879

Group type: EXPERIMENTAL
Intervention: Stimulating music
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (healthy persons)
Number of subjects: 21
Study: 11519934

Group type: EXPERIMENTAL
Intervention: Subliminal priming of secure base representations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal priming of positively valued, attachment-unrelated representations
Number of subjects: 0
Study: 9678794

Group type: EXPERIMENTAL
Intervention: G-CSF 6 microg/kg/12 h
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: G-CSF 8 microg/kg/12 h
Number of subjects: 48
Study: 8141451

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway ventilation at pressures of 15, 20, 25, and 30 cmH2O
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tracheal tube ventilation at pressures of 15, 20, 25, and 30 cmH2O
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway ventilation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tracheal tube ventilation
Number of subjects: 48
Study: 3046513

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol driven by oxygen
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nebulised salbutamol driven by compressed air
Number of subjects: 27
Study: 30279273

Group type: EXPERIMENTAL
Intervention: Urinary DKK3-to-creatinine level >4000 pg/mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary DKK3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rise in urinary DKK3 in patients with IgA nephropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stable or decreasing urinary DKK3 in patients with IgA nephropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary DKK3 levels
Number of subjects: 0
Study: 28709700

Group type: EXPERIMENTAL
Intervention: Prasugrel 10mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Clopidogrel 75mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 45
Study: 26580997

Group type: EXPERIMENTAL
Intervention: ALS-008176 (750 mg loading dose followed by 500 mg maintenance doses)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ALS-008176 (750 mg loading dose followed by 150 mg maintenance doses)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ALS-008176 (10 doses of 375 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ALS-008176 (all groups)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ALS-008176 (all groups with loading dose)
Number of subjects: 62
Study: 22924451

Group type: EXPERIMENTAL
Intervention: CO‐informed + BA (n = 80)
Number of subjects: 164

Group type: COMPARATOR
Intervention: BA only (n = 84)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Usual care (n = 506)
Number of subjects: 164
Study: 20622695

Group type: EXPERIMENTAL
Intervention: Lipostabil (0.5 ml injected in one eyelid)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Isotonic saline (0.5 ml injected in the opposite eyelid)
Number of subjects: 45
Study: 18461520

Group type: COMPARATOR
Intervention: 5-aminosalicylates (sulphasalazine 2 g/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral nutrition at home
Number of subjects: 0
Study: 15833934

Group type: EXPERIMENTAL
Intervention: Pentanucleotide insertion allele of the OB‐R gene
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: Pentanucleotide insertion allele of the OB‐R gene in women
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: Pentanucleotide insertion allele of the OB‐R gene in men
Number of subjects: 1429

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1429
Study: 12053846

Group type: EXPERIMENTAL
Intervention: Thermography for normal foot parameters
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thermography for foot stress fractures
Number of subjects: 90

Group type: COMPARATOR
Intervention: Thermography for trainees without complaints
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thermography
Number of subjects: 90
Study: 10595624

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg per day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8919898

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg eltanolone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg eltanolone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg eltanolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3 mg/kg thiopentone
Number of subjects: 40
Study: 1812137

Group type: EXPERIMENTAL
Intervention: L-tryptophan (50 mg/kg of body weight)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6305758

Group type: EXPERIMENTAL
Intervention: Intravenous corticotropin (120 U/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous hydrocortisone (300 mg/day)
Number of subjects: 66
Study: 30658605

Group type: COMPARATOR
Intervention: IV infusion of 10 IU oxytocin
Number of subjects: 4913

Group type: COMPARATOR
Intervention: IV bolus of 10 IU oxytocin
Number of subjects: 4913

Group type: EXPERIMENTAL
Intervention: IM injection of 10 IU oxytocin
Number of subjects: 4913
Study: 29746169

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acustimulation (TEA)
Number of subjects: 86
Study: 26672898

Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg twice-daily)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Dabigatran (110 mg twice-daily)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once-daily)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg once-daily)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice-daily)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Apixaban (2.5 mg twice-daily)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 330
Study: 24447606

Group type: EXPERIMENTAL
Intervention: T2-weighted and diffusion-weighted MRI
Number of subjects: 199
Study: 22549097

Group type: EXPERIMENTAL
Intervention: Dispersible levodopa/carbidopa microtablets (LC-5), 5/1.25 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard levodopa/carbidopa (LC-100), 100/25 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Dispersible levodopa/benserazide (LB-100), 100/25 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Carbidopa (from all formulations)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 3-O-MD (from all formulations)
Number of subjects: 19
Study: 19890258

Group type: EXPERIMENTAL
Intervention: Risperidone (2-6 mg/day)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 628
Study: 16770448

Group type: EXPERIMENTAL
Intervention: Patients with chronic neck pain attributing their pain to a motor vehicle accident.
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Men with chronic neck pain.
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Women with chronic neck pain.
Number of subjects: 419

Group type: COMPARATOR
Intervention: Comparison of chronic neck pain patients to chronic back pain controls.
Number of subjects: 419
Study: 14570663

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: IV sufentanil
Number of subjects: 40
Study: 10761164

Group type: EXPERIMENTAL
Intervention: Effervescent acetaminophen 1000 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Tablet acetaminophen 1000 mg
Number of subjects: 242

Group type: COMPARATOR
Intervention: Both acetaminophen formulations
Number of subjects: 242
Study: 9204788

Group type: EXPERIMENTAL
Intervention: Preoperative acetaminophen (15 mg/kg oral)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Postoperative acetaminophen (20 mg/kg rectal)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 28
Study: 1407888

Group type: EXPERIMENTAL
Intervention: Silastic rings
Number of subjects: 102

Group type: COMPARATOR
Intervention: Electrocoagulation
Number of subjects: 102
Study: 3907639

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (Tebonin)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31023524

Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine (625 mg/m2 twice per day) with cyclophosphamide (50 mg/d)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine with cyclophosphamide
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: NLR baseline < 3 versus ≥ 3
Number of subjects: 23
Study: 28884342

Group type: EXPERIMENTAL
Intervention: Pre-operative guided imagery (GIM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (GIM and control)
Number of subjects: 38
Study: 26270199

Group type: EXPERIMENTAL
Intervention: HeProCalc program for heparin and protamine dosing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional heparin and protamine dosing based on body weight
Number of subjects: 40
Study: 24618345

Group type: EXPERIMENTAL
Intervention: Manual therapy (spinal manipulation, spinal mobilization, stretching and massage)
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Manual therapy excluding spinal manipulation
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Manual therapy excluding stretching
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Manual therapy (all groups)
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 767
Study: 21941223

Group type: EXPERIMENTAL
Intervention: Maintenance of mean arterial pressure (MAP) above 60 mmHg during surgery
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Determination of critical MAP value
Number of subjects: 32
Study: 20571294

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg IV before anesthesia)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Ketolgan (30 mg IV before anesthesia)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: History of migraine
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Migraine-free patients
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Opioids for analgesia
Number of subjects: 153
Study: 18727886

Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Novolizer
Number of subjects: 112

Group type: COMPARATOR
Intervention: Accuhaler
Number of subjects: 112
Study: 15961941

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer (RMGI)
Number of subjects: 37

Group type: COMPARATOR
Intervention: High-strength traditional glass ionomer cement (GIC)
Number of subjects: 37
Study: 12170215

Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinemia (defined as >95th percentile in healthy individuals)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Control group (patients with patent grafts)
Number of subjects: 449
Study: 10519604

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 41

Group type: COMPARATOR
Intervention: Apraclonidine 1.0%
Number of subjects: 41
Study: 8719981

Group type: EXPERIMENTAL
Intervention: Perfusion scintigraphy in combination with ventilation studies
Number of subjects: 25

Group type: COMPARATOR
Intervention: Spiral CT
Number of subjects: 25
Study: 1787024

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 240

Group type: COMPARATOR
Intervention: 45-day detoxification
Number of subjects: 240
Study: 6112324

Group type: EXPERIMENTAL
Intervention: Breathing oxygen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breathing oxygen for five or fifteen minutes before exercise (predose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breathing oxygen during exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Portable oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardised progressive exercise test on a treadmill
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Submaximum exercise with oxygen
Number of subjects: 0
Study: 30935375

Group type: EXPERIMENTAL
Intervention: Single dose of nonavalent HPV vaccine (GARDASIL 9)
Number of subjects: 0
Study: 28099472

Group type: EXPERIMENTAL
Intervention: Elastic Tape (ET)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham Tape (ST)
Number of subjects: 13
Study: 25844831

Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Alcohol and rumination group
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Alcohol and rumination condition
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo and uninstructed condition
Number of subjects: 138
Study: 24150660

Group type: EXPERIMENTAL
Intervention: Combination acetaminophen (48 mg·kg(‐1)·day(‐1)) and ibuprofen (24 mg·kg(‐1)·day(‐1))
Number of subjects: 152

Group type: COMPARATOR
Intervention: Acetaminophen alone (48 mg·kg(‐1)·day(‐1))
Number of subjects: 152

Group type: COMPARATOR
Intervention: Ibuprofen alone (24 mg·kg(‐1)·day(‐1))
Number of subjects: 152
Study: 21341925

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN) 0-, 7-, 14-, or 21-mg doses
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Smoking (independent of TN dose)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN)
Number of subjects: 124
Study: 19236536

Group type: EXPERIMENTAL
Intervention: One-stage full-mouth disinfection (FMD)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (FM-SRP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Quadrant scaling and root planing (Q-SRP)
Number of subjects: 25
Study: 17297027

Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil (Malarone)
Number of subjects: 0
Study: 12737786

Group type: EXPERIMENTAL
Intervention: Portable ultrasound device
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard platform (gold standard)
Number of subjects: 211
Study: 11188776

Group type: EXPERIMENTAL
Intervention: IVIG treatment (immunoglobulin 10% 1 g/kg bodyweight)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo (0.1 g albumin/vial)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: IVIG treatment
Number of subjects: 318
Study: 9538657

Group type: EXPERIMENTAL
Intervention: 3 x 80 mg sotalol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 2 x 160 mg sotalol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both doses of sotalol
Number of subjects: 34
Study: 8404175

Group type: EXPERIMENTAL
Intervention: Theophylline therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 38
Study: 3096218

Group type: EXPERIMENTAL
Intervention: SF-SP
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SF-SP plus BH-AC
Number of subjects: 58